קלטרה 200 מג50 מג טבליות ישראל - עברית - Ministry of Health

קלטרה 200 מג50 מג טבליות

abbvie biopharmaceuticals ltd, israel - lopinavir; ritonavir - טבליות מצופות פילם - ritonavir 50 mg; lopinavir 200 mg - lopinavir - lopinavir - kaletra is indicated in combination with other antiretroviral agents for the treatment of hiv-1 infection.

קלטרה תמיסה ישראל - עברית - Ministry of Health

קלטרה תמיסה

abbvie biopharmaceuticals ltd, israel - lopinavir; ritonavir - תמיסה (פומי) - ritonavir 20 mg/ml; lopinavir 80 mg/ml - ritonavir

קלטרה תמיסה ישראל - עברית - Ministry of Health

קלטרה תמיסה

abbvie biopharmaceuticals ltd, israel - lopinavir; ritonavir - תמיסה (פומי) - ritonavir 20 mg/ml; lopinavir 80 mg/ml - ritonavir

הרספטין 440 מג I.V ישראל - עברית - Ministry of Health

הרספטין 440 מג i.v

roche pharmaceuticals (israel) ltd - trastuzumab - תמיסה לאינפוזיה - trastuzumab 440 mg/ml - trastuzumab - trastuzumab - herceptin is indicated for the treatment of patients with metastatic breast cancer who have tumours that overexpress her2: 1. as a single agent for the treatment of those patients who have received one or more chemotherapy regiments for their metastatic disease. 2. in combination with paclitaxel or docetaxel for the treatment of those patients who have not received chemotherapy for their metastatic disease. 3. herceptin in combination with an aromatase inhibitor for the treatment of postmenopausal patients with hormone-receptor positive metastatic breast cancer. early breast cancer (ebc) :herceptin is indicated to treat patients with her2-positive early breast cancer following surgery and chemotherapy (neoadjuvant or adjuvant) either alone or in combination with chemotherapy excluding anthracyclines. herceptin should only be used in patients whose tumors have either her2 overexpression or her2 gene amplification as determined by an accurate and validated assay.her2 metastatic gastric cancer (mgc)herceptin in

אוגיברי 420 מג ישראל - עברית - Ministry of Health

אוגיברי 420 מג

dexcel ltd, israel - trastuzumab - trastuzumab 420 mg/vial - trastuzumab

הרספטין 600 מג5 מל S.C ישראל - עברית - Ministry of Health

הרספטין 600 מג5 מל s.c

roche pharmaceuticals (israel) ltd - trastuzumab - תמיסה להזרקה - trastuzumab 600 mg / 5 ml - trastuzumab

טוקייסה 150 מג ישראל - עברית - Ministry of Health

טוקייסה 150 מג

merck sharp & dohme (israel-1996) ltd - tucatinib - טבליות מצופות פילם - tucatinib 150 mg - tucatinib

טוקייסה 50 מג ישראל - עברית - Ministry of Health

טוקייסה 50 מג

merck sharp & dohme (israel-1996) ltd - tucatinib - טבליות מצופות פילם - tucatinib 50 mg - tucatinib

קסאלקורי 200 מג ישראל - עברית - Ministry of Health

קסאלקורי 200 מג

pfizer pharmaceuticals israel ltd - crizotinib - קפסולות - crizotinib 200 mg - crizotinib - crizotinib - xalkori is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (nsclc) that is anaplastic lymphoma kinase (alk)-positive.

קסאלקורי 200 מג ישראל - עברית - Ministry of Health

קסאלקורי 200 מג

pfizer pharmaceuticals israel ltd - crizotinib - קפסולות - crizotinib 200 mg - crizotinib - crizotinib - xalkori is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (nsclc) that is anaplastic lymphoma kinase (alk)-positive.